Celecoxib microparticles for inhalation in COVID-19-related acute respiratory distress syndrome
MC Villa-Hermosilla, S Negro, E Barcia, C Hurtado… - Pharmaceutics, 2022 - mdpi.com
Inhalation therapy is gaining increasing attention for the delivery of drugs destined to treat
respiratory disorders associated with cytokine storms, such as COVID-19. The pathogenesis …
respiratory disorders associated with cytokine storms, such as COVID-19. The pathogenesis …
Carrier-Free Inhalable Dry Microparticles of Celecoxib: Use of the Electrospraying Technique
Upregulation of cyclooxygenase (COX-2) plays an important role in lung cancer
pathogenesis. Celecoxib (CLX), a selective COX-2 inhibitor, may have beneficial effects in …
pathogenesis. Celecoxib (CLX), a selective COX-2 inhibitor, may have beneficial effects in …
Fabrication of Celecoxib PVP Microparticles Stabilized by Gelucire 48/16 via Electrospraying for Enhanced Anti-Inflammatory Action
Electrospraying (ES) technology is considered an efficient micro/nanoparticle fabrication
technique with controlled dimensions and diverse morphology. Gelurice® 48/16 (GLR) has …
technique with controlled dimensions and diverse morphology. Gelurice® 48/16 (GLR) has …
The nano-based theranostics for respiratory complications of COVID-19
M Ghasemzad, SMR Hashemian… - Drug Development …, 2021 - Taylor & Francis
High morbidity and mortality caused by the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) has made coronavirus disease 2019 (COVID-19) the leading challenge for …
(SARS-CoV-2) has made coronavirus disease 2019 (COVID-19) the leading challenge for …
Inhaled ACE2-engineered microfluidic microsphere for intratracheal neutralization of COVID-19 and calming of the cytokine storm
Z Wang, L Xiang, F Lin, Z Cai, H Ruan, J Wang, J Liang… - Matter, 2022 - cell.com
The SARS-CoV-2 pandemic spread worldwide unabated. However, achieving protection
from the virus in the whole respiratory tract, avoiding blood dissemination, and calming the …
from the virus in the whole respiratory tract, avoiding blood dissemination, and calming the …
Formulation and optimization of celecoxib-loaded PLGA nanoparticles by the Taguchi design and their in vitro cytotoxicity for lung cancer therapy
The objective of the present study was to develop, evaluate and optimize a polymeric
nanoparticle (NP) system containing Cxb for pulmonary delivery of Cxb in the treatment of …
nanoparticle (NP) system containing Cxb for pulmonary delivery of Cxb in the treatment of …
Characteristics of SARS-CoV2 that may be useful for nanoparticle pulmonary drug delivery
M Rabiei, S Kashanian, SS Samavati… - Journal of drug …, 2022 - Taylor & Francis
As a non-invasive method of local and systemic drug delivery, the administration of active
pharmaceutical ingredients (APIs) via the pulmonary route represents an ideal approach for …
pharmaceutical ingredients (APIs) via the pulmonary route represents an ideal approach for …
Dry powder formulation of azithromycin for COVID-19 therapeutics
SHY Chan, K Sheikh, MG Zariwala… - Journal of …, 2023 - Taylor & Francis
Azithromycin is an antibiotic proposed as a treatment for the coronavirus disease 2019
(COVID-19) due to its immunomodulatory activity. The aim of this study is to develop dry …
(COVID-19) due to its immunomodulatory activity. The aim of this study is to develop dry …
Inhibition of SARS-CoV-2-Induced NLRP3 Inflammasome-Mediated Lung Cell Inflammation by Triphala-Loaded Nanoparticle Targeting Spike Glycoprotein S1
C Chittasupho, S Umsumarng, K Srisawad, P Arjsri… - Pharmaceutics, 2024 - mdpi.com
The COVID-19 pandemic, caused by SARS-CoV-2, poses a significant global health threat.
The spike glycoprotein S1 of the SARS-CoV-2 virus is known to induce the production of pro …
The spike glycoprotein S1 of the SARS-CoV-2 virus is known to induce the production of pro …
Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers
RR Patlolla, M Chougule, AR Patel, T Jackson… - Journal of Controlled …, 2010 - Elsevier
The aim of the current study was to encapsulate celecoxib (Cxb) in the nanostructured lipid
carrier (Cxb-NLC) nanoparticles and evaluate the lung disposition of nanoparticles following …
carrier (Cxb-NLC) nanoparticles and evaluate the lung disposition of nanoparticles following …